Cytophage Technologies (TSXV:CYTO) EV-to-FCF : 10.47 (As of Jun. 03, 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cytophage Technologies's Enterprise Value is C$20.33 Mil. Cytophage Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was C$1.94 Mil. Therefore, Cytophage Technologies's EV-to-FCF for today is 10.47.

The historical rank and industry rank for Cytophage Technologies's EV-to-FCF or its related term are showing as below:

TSXV:CYTO' s EV-to-FCF Range Over the Past 10 Years
Min: -33.32 Med: 0 Max: 14.72
Current: 13.34

During the past 3 years, the highest EV-to-FCF of Cytophage Technologies was 14.72. The lowest was -33.32. And the median was 0.00.

TSXV:CYTO's EV-to-FCF is ranked worse than
56.61% of 378 companies
in the Biotechnology industry
Industry Median: 8.345 vs TSXV:CYTO: 13.34

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-03), Cytophage Technologies's stock price is C$0.45. Cytophage Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.045. Therefore, Cytophage Technologies's PE Ratio for today is 10.00.

Cytophage Technologies EV-to-FCF Historical Data

The historical data trend for Cytophage Technologies's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies EV-to-FCF Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

EV-to-FCF

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
EV-to-FCF	-	-	-	-	-

Competitive Comparison of Cytophage Technologies's EV-to-FCF

For the Biotechnology subindustry, Cytophage Technologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytophage Technologies's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's EV-to-FCF falls into.

Cytophage Technologies EV-to-FCF Calculation

Cytophage Technologies's EV-to-FCF for today is calculated as:

EV-to-FCF	=	Enterprise Value (Today)	/	Free Cash Flow (TTM)
	=	20.334	/	1.942
	=	10.47

Cytophage Technologies's current Enterprise Value is C$20.33 Mil.
Cytophage Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.94 Mil.

Cytophage Technologies (TSXV:CYTO) EV-to-FCF Explanation

Cytophage Technologies's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.45	/	0.045
	=	10.00

Cytophage Technologies's share price for today is C$0.45.
Cytophage Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.045.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Cytophage Technologies EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » EV-to-FCF

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.